CY1117985T1 - Ιντερφερονη (interferon) βητα για χρηση στην θεραπεια ασθενειας του κατωτερου αναπνευστικου συστηματος που προκαλειται απο γριπη - Google Patents

Ιντερφερονη (interferon) βητα για χρηση στην θεραπεια ασθενειας του κατωτερου αναπνευστικου συστηματος που προκαλειται απο γριπη

Info

Publication number
CY1117985T1
CY1117985T1 CY20161100897T CY161100897T CY1117985T1 CY 1117985 T1 CY1117985 T1 CY 1117985T1 CY 20161100897 T CY20161100897 T CY 20161100897T CY 161100897 T CY161100897 T CY 161100897T CY 1117985 T1 CY1117985 T1 CY 1117985T1
Authority
CY
Cyprus
Prior art keywords
breath
respiratory system
interferon beta
disease treatment
treatment
Prior art date
Application number
CY20161100897T
Other languages
English (en)
Inventor
Victoria Jane Tear
James Jonathan Welch Roberts
Phillip David Monk
Original Assignee
Synairgen Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1004144.0A external-priority patent/GB201004144D0/en
Priority claimed from GBGB1008114.9A external-priority patent/GB201008114D0/en
Application filed by Synairgen Research Limited filed Critical Synairgen Research Limited
Publication of CY1117985T1 publication Critical patent/CY1117985T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ένας παράγοντας που επιλέγεται από: (a) ιντερφερόνη (interferon)-β (IFN-β), (b) ένα παράγοντα που αυξάνει την έκφραση της IFN-β, ή (c) ένα πολύ-νουκλεοτίδιο (polynucleotide) που είναι ικανό να εκφράζει το (a) ή (b), για χρήση στην θεραπεία ατόμων με ασθένεια κατώτερου αναπνευστικού συστήματος που έχει αναπτυχθεί κατά την διάρκεια ή μετά από μία διαπιστωμένη ILI, όπου η εν λόγω θεραπεία είναι με παροχή του εν λόγω φαρμάκου στις αναπνευστικές οδούς.
CY20161100897T 2010-03-12 2016-09-12 Ιντερφερονη (interferon) βητα για χρηση στην θεραπεια ασθενειας του κατωτερου αναπνευστικου συστηματος που προκαλειται απο γριπη CY1117985T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1004144.0A GB201004144D0 (en) 2010-03-12 2010-03-12 Therapy for influenza like illness
GBGB1008114.9A GB201008114D0 (en) 2010-05-17 2010-05-17 Therapy for influenza like illness
PCT/GB2011/050480 WO2011110861A2 (en) 2010-03-12 2011-03-10 Therapy for influenza like illness

Publications (1)

Publication Number Publication Date
CY1117985T1 true CY1117985T1 (el) 2017-05-17

Family

ID=44563925

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100897T CY1117985T1 (el) 2010-03-12 2016-09-12 Ιντερφερονη (interferon) βητα για χρηση στην θεραπεια ασθενειας του κατωτερου αναπνευστικου συστηματος που προκαλειται απο γριπη

Country Status (17)

Country Link
US (1) US9421243B2 (el)
EP (1) EP2544705B1 (el)
JP (1) JP5926200B2 (el)
CN (2) CN107050431A (el)
CA (1) CA2792727C (el)
CY (1) CY1117985T1 (el)
DK (1) DK2544705T3 (el)
ES (1) ES2592528T3 (el)
HR (1) HRP20161158T1 (el)
HU (1) HUE029250T2 (el)
LT (1) LT2544705T (el)
PL (1) PL2544705T3 (el)
PT (1) PT2544705T (el)
RS (1) RS55154B1 (el)
SI (1) SI2544705T1 (el)
SM (1) SMT201600334B (el)
WO (1) WO2011110861A2 (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4181944A1 (en) * 2020-07-20 2023-05-24 Synairgen Research Limited Inhaled interferon-beta for improving outcome in sars-cov-2 infected patients
GB202014114D0 (en) 2020-09-08 2020-10-21 Synairgen Res Ltd Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030609A (en) 1995-05-19 2000-02-29 Case Western Reserve University Method and composition for treating paramyxovirus
PE20010540A1 (es) * 1999-07-30 2001-05-15 Procter & Gamble Composicion de fitoalexinas estilbenicas util para la profilaxis y tratamiento de sintomas asociados con el resfriado y enfermedades similares a la influenza
GB2362884A (en) 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
AU2004270102B2 (en) * 2003-05-23 2009-10-01 Pestka Biomedical Laboratories, Inc. Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
EP1641485A4 (en) 2003-06-09 2009-06-24 Genome Inst Of Singapore INHIBITION OF SARS CORONAVIRUS INFECTION USING ANTIVIRAL DRUGS CLINICALLY TESTED
CN101001644B (zh) * 2003-08-28 2011-09-21 辉阳科技美国公司 空间构象改变的干扰素及其应用
GB0405634D0 (en) * 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
GB0518425D0 (en) * 2005-09-09 2005-10-19 Imp College Innovations Ltd Methods
CN1927389B (zh) * 2004-09-10 2012-11-14 北京金迪克生物技术研究所 含有人干扰素的药物组合物在制备预防或/和治疗呼吸道病毒感染疾病药物方面的应用
CN1927388B (zh) * 2004-09-10 2011-02-02 北京金迪克生物技术研究所 含有人干扰素的药物组合物
US20080292586A1 (en) * 2005-02-04 2008-11-27 Karen Jervis Method and Use of Interferon Compositions For the Treatment of Avian Influenza
CA2622016A1 (en) 2005-09-09 2007-03-15 Imperial Innovations Limited Interferon lambda therapy for treatment of respiratory diseases
JP2009515933A (ja) * 2005-11-18 2009-04-16 アレス トレーディング ソシエテ アノニム インフルエンザにおけるインターフェロン
GB0609410D0 (en) 2006-05-12 2006-06-21 Viragen Inc Method for the production of a type 1 interfemon in a transgenic avian
WO2008143892A1 (en) 2007-05-18 2008-11-27 New York University Method of treating tuberculosis with interferons
CA2589613A1 (en) 2007-05-18 2008-11-18 Synairgen Plc Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly

Also Published As

Publication number Publication date
LT2544705T (lt) 2016-10-10
CA2792727A1 (en) 2011-09-15
PT2544705T (pt) 2016-09-21
SI2544705T1 (sl) 2016-11-30
WO2011110861A3 (en) 2011-11-24
JP5926200B2 (ja) 2016-05-25
CA2792727C (en) 2019-06-04
EP2544705B1 (en) 2016-08-31
US20130064792A1 (en) 2013-03-14
CN107050431A (zh) 2017-08-18
US9421243B2 (en) 2016-08-23
CN102883741A (zh) 2013-01-16
DK2544705T3 (en) 2016-09-19
HUE029250T2 (en) 2017-04-28
RS55154B1 (sr) 2017-01-31
HRP20161158T1 (hr) 2016-11-18
SMT201600334B (it) 2016-11-10
WO2011110861A2 (en) 2011-09-15
PL2544705T3 (pl) 2017-02-28
EP2544705A2 (en) 2013-01-16
JP2013522282A (ja) 2013-06-13
ES2592528T3 (es) 2016-11-30

Similar Documents

Publication Publication Date Title
CY1123571T1 (el) Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
CY1120030T1 (el) Διπλοι glp1/gip ή τριγωνικοι αγωνιστες glp1/gip/ γλυκαγονης
AR092925A1 (es) Derivados de exendina-4 como agonistas duales de glp1 / glucagon
BR112016022465A2 (pt) agonistas de receptores de glp-1/glucagon duplo peptídicos derivados de exendina-4
CL2015000870A1 (es) Análogos de 2' -cloro nucleósido para infección por vhc.
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
UY36779A (es) Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
JOP20200230A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
MY190867A (en) ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
UA118354C2 (uk) Антитіло до рецептора колонієстимулювального фактора (кфс-1r)
MX2022002056A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
WO2015092404A3 (en) Intubating airway device
BR112017013765A2 (pt) métodos para uso de oligonucleotídeos antisense smad7
AR100115A1 (es) Dispositivo para presión positiva continua
UY35771A (es) Tienouracil-carboxamidas cíclicas y su uso
CY1117985T1 (el) Ιντερφερονη (interferon) βητα για χρηση στην θεραπεια ασθενειας του κατωτερου αναπνευστικου συστηματος που προκαλειται απο γριπη
BR112018002140A2 (pt) USO DE MARCADORES MOLECULARES IL-3, IL-33 e IL-12p40 PARA CARACTERIZAR ASGRAVIDADES DAS INFECÇÕES RESPIRATÓRIAS POR VÍRUS RESPIRATÓRIO SINCITIAL E METAPNEUMOVÍRUS HUMANO
EA201790991A1 (ru) Способ лечения с использованием пегилированного интерферона
MX2023011202A (es) Agonistas de receptores alfa de ácido retinoico (rara) para el tratamiento de leucemia mieloide aguda (aml) y síndrome mielodisplásico (mds).
EA201692371A1 (ru) 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування
PH12017501979A1 (en) Pharmaceutical compound
MX2018004984A (es) Formulaciones de isotretinoina y usos y metodos de las mismas.
EA202191327A1 (ru) Лекарственные формы терапевтических препаратов от гриппа